The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action
-
Published:2024-03
Issue:
Volume:
Page:
-
ISSN:1050-1738
-
Container-title:Trends in Cardiovascular Medicine
-
language:en
-
Short-container-title:Trends in Cardiovascular Medicine
Author:
Alexiadou KleopatraORCID,
Hartley Adam,
Tan Tricia M-M,
Khamis Ramzi
Funder
British Heart Foundation
Reference36 articles.
1. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on;Boutari;Metabolism.,2022
2. The Epidemiology of Obesity: a Big Picture;Hruby;Pharmacoeconomics,2015
3. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments;Ruze;Front. Endocrinol. (Lausanne),2023
4. Once-weekly semaglutide in adults with overweight or obesity;Wilding;N. Engl. J. Med.,2021
5. Semaglutide 2.4mg once a week in adults with overweight or obesity, and type 2 diabetes (step 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial;Davies;Lancet,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献